Photo of Bruce E. Johnson,   M.D.

Bruce E. Johnson, M.D.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5314
Fax: (617) 632-5786


bejohnson@partners.org

Bruce E. Johnson, M.D.

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Professor of Medicine, Adult Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Member, Center Scientific Council

Research Abstract

The translational research on patients with adenocarcinoma of the lung here at the Dana- Farber/Harvard Cancer Center has helped identify patient subsets that respond differently to targeted agents. Women, patients with adenocarcinoma, and those who do not smoke cigarettes are more likely to have a favorable response to gefitinib and erlotinib therapy (Iressa and Tarceva) than patients with other types of lung cancer and men respectively. This prompted my laboratory to assemble tumor cell lines from women with adenocarcinoma who either did or did not smoke cigarettes to characterize their response to gefitinib. A team composed of our laboratory and the laboratory led by Dr. Sellers and Meyerson at the Dana-Farber Cancer Institute discovered that most patients who have a clinical response to gefitinib treatment have either point mutations or deletion of amino acids from the tyrosine kinase domain of the epidermal growth factor receptor. Our laboratory showed lung cancer cell lines with epidermal growth factor cell lines with these point mutations or deletions are 100 fold more sensitive to treatment gefitinib than cell lines with wild type sequence of the epidermal growth factor receptor. The lung cancer cell lines with mutations in the epidermal growth factor receptor treated with 100 nM of gefitinib have downregulation of phosphorylated epidermal growth factor receptor. This also leads to downregulation of the downstream targets including phospho-Akt and phospho-Erk1/2 kinase. Treatment of lung cancer cells with mutated epidermal growth factor receptor with 1 micromolar gefitinib leads to apoptosis while the cells with wild type epidermal growth factor receptor undergo a G1/S arrest. Future studies will study the relationship between different mutations in the epidermal growth factor receptor, their susceptibility to different epidermal growth factor receptor inhibitors, and the signaling pathways. Prospective trials will test the impact of these epidermal growth factor receptor mutations on the treatment of patients with non-small cell lung cancer. The studies will include erlotinib treatment in previously untreated elderly patients with advanced non-small cell lung cancer (older than 70) and women with adenocarcinoma who are either never smokers or former smokers. These patients will have their tumor DNA studied for the epidermal growth factor receptor sequence, and their response, response duration, subsequent response to other chemotherapy, and survival will be recorded. This will be done to determine if there is a relationship between the epidermal growth factor receptor sequence and the outcome of patients with non-small cell lung cancer after treatment with erlotinib.

Publications

Powered by Harvard Catalyst
  • Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer 2015. PubMed
  • Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. 2015; 6:4527-36. PubMed
  • Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ, . Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience. J Thorac Oncol 2015. PubMed
  • Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE. Interstitial lung abnormalities in treatment-na誰ve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol 2015. PubMed
  • Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 2014. PubMed
  • Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol 2014; 9:1411-7. PubMed
  • Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 2014. PubMed
  • Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE, . Realizing the potential of plasma genotyping in an age of genotype-directed therapies. Journal of the National Cancer Institute 2014. PubMed
  • Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical designs in phase I expansion cohorts: the dana-farber/harvard cancer center experience. Journal of the National Cancer Institute 2014. PubMed
  • Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998-2006. PubMed
  • Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 2014; 271:6-27. PubMed
  • Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013; 73:6770-9. PubMed
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 2013; 119:3761-8. PubMed
  • Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:3926-34. PubMed
  • Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol 2013; 8:1434-7. PubMed
  • Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013; 19:4532-40. PubMed
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 2013; 8:1059-68. PubMed
  • Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 2013; 201:W64-71. PubMed
  • Cardarella S, Johnson BE. Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts. Journal of the National Cancer Institute 2013. PubMed
  • Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer 2013. PubMed
  • Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 79:283-8. PubMed
  • Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013; 8:179-84. PubMed
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012; 7:1767-74. PubMed
  • Shinagare AB, Okajima Y, Oxnard GR, Dipiro PJ, Johnson BE, Hatabu H, Nishino M. Unsuspected pulmonary embolism in lung cancer patients: Comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer 2012; 78:161-6. PubMed
  • Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2012; 7:1594-601. PubMed
  • Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25. PubMed
  • Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150:1107-20. PubMed
  • Heon S, Johnson BE. Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2012; 144:S39-42. PubMed
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012; 18:4406-14. PubMed
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal 2012; 32 Suppl 1:S117-24. PubMed
  • Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging 2012; 12:225-35. PubMed
  • Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol 2011; 18:424-36. PubMed
  • Cooley ME, Emmons KM, Haddad R, Wang Q, Posner M, Bueno R, Cohen TJ, Johnson BE. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer 2011. PubMed
  • Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol 2010; 18:54-62. PubMed
  • Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16:5873-82. PubMed
  • Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010; 195:W221-8. PubMed
  • Paulus JK, Zhou W, Kraft P, Johnson BE, Lin X, Christiani DC. Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women. Lung Cancer 2010. PubMed
  • Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11:619-26. PubMed
  • Paulus JK, Asomaning K, Kraft P, Johnson BE, Lin X, Christiani DC. Parity and risk of lung cancer in women. Am J Epidemiol 2010; 171:557-63. PubMed
  • Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16:1561-71. PubMed
  • Johnson BE, Johnson CA. ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women. Ann Intern Med 2010; 152:JC-28. PubMed
  • Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28:357-60. PubMed
  • Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28:193-201. PubMed
  • Hammerman PS, Jänne PA, Johnson BE. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2009; 15:7502-7509. PubMed
  • Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 2009; 115:4156-66. PubMed
  • Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009; 15:5317-22. PubMed
  • Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol 2009; 4:1156-62. PubMed
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216-23. PubMed
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15:5267-73. PubMed
  • Barletta JA,Perner S,Iafrate AJ,Yeap BY,Weir BA,Johnson LA,Johnson BE,Meyerson M,Rubin MA,Travis WD,Loda M,Chirieac LR. Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma. J Cell Mol Med 2010; 13:1977-86. PubMed
  • Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138:405-11. PubMed
  • Hanrahan EO,Ryan AJ,Mann H,Kennedy SJ,Langmuir P,Natale RB,Herbst RS,Johnson BE,Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15:3600-9. PubMed
  • Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15:3484-94. PubMed
  • Zellos L,Richards WG,Capalbo L,Jaklitsch MT,Chirieac LR,Johnson BE,Bueno R,Sugarbaker DJ. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2009; 137:453-8. PubMed
  • McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS. Adopting helical CT screening for lung cancer : potential health consequences during a 15-year period. Cancer 2008; 113:3440-9. PubMed
  • Heymach JV,Paz-Ares L,De Braud F,Sebastian M,Stewart DJ,Eberhardt WE,Ranade AA,Cohen G,Trigo JM,Sandler AB,Bonomi PD,Herbst RS,Krebs AD,Vasselli J,Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:5407-15. PubMed
  • Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14:6963-73. PubMed
  • Ding L,Getz G,Wheeler DA,Mardis ER,McLellan MD,Cibulskis K,Sougnez C,Greulich H,Muzny DM,Morgan MB,Fulton L,Fulton RS,Zhang Q,Wendl MC,Lawrence MS,Larson DE,Chen K,Dooling DJ,Sabo A,Hawes AC,Shen H,Jhangiani SN,Lewis LR,Hall O,Zhu Y,Mathew T,Ren Y,Yao J,Scherer SE,Clerc K,Metcalf GA,Ng B,Milosavljevic A,Gonzalez-Garay ML,Osborne JR,Meyer R,Shi X,Tang Y,Koboldt DC,Lin L,Abbott R,Miner TL,Pohl C,Fewell G,Haipek C,Schmidt H,Dunford-Shore BH,Kraja A,Crosby SD,Sawyer CS,Vickery T,Sander S,Robinson J,Winckler W,Baldwin J,Chirieac LR,Dutt A,Fennell T,Hanna M,Johnson BE,Onofrio RC,Thomas RK,Tonon G,Weir BA,Zhao X,Ziaugra L,Zody MC,Giordano T,Orringer MB,Roth JA,Spitz MR,Wistuba II,Ozenberger B,Good PJ,Chang AC,Beer DG,Watson MA,Ladanyi M,Broderick S,Yoshizawa A,Travis WD,Pao W,Province MA,Weinstock GM,Varmus HE,Gabriel SB,Lander ES,Gibbs RA,Meyerson M,Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75. PubMed
  • Saad AG,Yeap BY,Thunnissen FB,Pinkus GS,Pinkus JL,Loda M,Sugarbaker DJ,Johnson BE,Chirieac LR. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 2008; 113:2129-38. PubMed
  • Dahlberg SE,Gray RJ,Johnson BE. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol 2008; 26:4233-5. PubMed
  • Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008; 99:245-52. PubMed
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS. Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study. Radiology 2008; 248:278-87. PubMed
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. J Clin Oncol 2008; 26:2442-9. PubMed
  • Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr. Small cell lung cancer. J Natl Compr Canc Netw 2008; 6:294-314. PubMed
  • Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26:983-94. PubMed
  • Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450:893-8. PubMed
  • Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13:6175-81. PubMed
  • Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Sp. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25:4270-7. PubMed
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448:807-10. PubMed
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, J. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007; 316:1039-43. PubMed
  • Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, J. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007; 67:4933-9. PubMed
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, J. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-6. PubMed
  • Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007; 109:924-32. PubMed
  • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 world health organization pathologic criteria. J Thorac Oncol 2007; 1:S13-9. PubMed
  • Johnson BE, Jackman D, J. Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 2006; 58 Suppl 7:5-9. PubMed
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borr. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer. J Clin Invest 2006; 116:2695-706. PubMed
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, J. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24:4517-20. PubMed
  • Sequist LV, Joshi VA, J. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006; 12:4403s-8s. PubMed
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, J. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006; 12:4365s-71s. PubMed
  • Johnson BE, J. Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. Clin Cancer Res 2006; 12:4436s-40s. PubMed
  • J. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12:4416s-20s. PubMed
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, J. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-14. PubMed
  • Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC,. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4:602-22. PubMed
  • Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006; 4:631-8. PubMed
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, J. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9:485-95. PubMed
  • J. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12:751-8. PubMed
  • Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006; 12:888-96. PubMed
  • Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ,. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2005; 24:190-205. PubMed
  • Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, J. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005; 11:8122-30. PubMed
  • Myers JN, O'neil KM, Walsh TE, Hoffmeister KJ, Venzon DJ, Johnson BE. The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. Chest 2005; 128:3261-8. PubMed
  • Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366:1385-96. PubMed
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-9. PubMed
  • Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA,. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-9. PubMed
  • Johnson BE, J. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005; 65:7525-9. PubMed
  • Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, J. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185-94. PubMed
  • Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res 2005; 11:4981s-4983s. PubMed
  • Johnson BE, Rabin MS. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res 2005; 11:5022s-5026s. PubMed
  • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005; 23:3279-87. PubMed
  • J. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23:3227-34. PubMed
  • Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2005; 11:3417-24. PubMed
  • Engelman JA, J. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005; 102:3788-93. PubMed
  • Kobayashi S, Boggon TJ, Dayaram T, J. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-92. PubMed
  • Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005; 68:500-10. PubMed
  • Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, J. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64:7241-4. PubMed
  • Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15:1187-93. PubMed
  • Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004; 10:4199s-4204s. PubMed
  • Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res 2004; 10:4254S-7S. PubMed
  • Paez JG, J. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004; 304:1497-500. PubMed
  • Johnson BE. Imatinib for small cell lung cancer, aiming for a target in vivo. Clin Cancer Res 2004; 10:3235-6. PubMed
  • Wirth LJ, Carter MR, J. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44:213-20. PubMed
  • J. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004; 44:221-30. PubMed
  • J. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004; 23:2716-26. PubMed
  • Johnson BE, J. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:309-22. PubMed
  • Cross CK, Berman S, Buswell L, Johnson B, Baldini EH. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58:1098-105. PubMed
  • Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9:5880-7. PubMed
  • Means-Markwell M, Linnoila RI, Williams J, J. Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. Clin Cancer Res 2003; 9:5915-21. PubMed
  • Johnson BE. Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst 2003; 95:1422-4. PubMed
  • Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 2003; 41 Suppl 1:S49-53. PubMed
  • Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003; 98:135-43. PubMed
  • Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, J. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res 2003; 9:1698-704. PubMed
  • Freidlin B, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2003; 9:917-22. PubMed
  • Fujishita T, Loda M, Turner RE, Gentler M, Kashii T, Breathnach OS, Johnson BE. Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology 2003; 64:399-406. PubMed
  • Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002; 62:6304-11. PubMed
  • J. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95:1528-38. PubMed
  • J. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002; 62:5242-7. PubMed
  • Breathnach OS, Kasturi V, Kaye F, Herscher L, Georgiadis MS, Edison M, Schuler BS, Pizzella P, Steinberg SM, O'Neil K, Johnson BE. Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer. Am J Clin Oncol 2002; 25:269-73. PubMed
  • Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002; 23:225-39. PubMed
  • Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-7. PubMed
  • Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7:3942-9. PubMed
  • Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-5. PubMed
  • Johnson BE,. NCCN: Small cell lung cancer. Cancer Control 2002; 8:32-43. PubMed
  • Johnson BE, Johnson CA. Cardiovascular disease and differences between the sexes. Am Fam Physician 2001; 63:1290, 1292. PubMed
  • Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19:1734-42. PubMed
  • Johnson BE. Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer. J Natl Cancer Inst 2001; 93:254-5. PubMed
  • J. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy. Oncology 2001; 61:175-83. PubMed
  • Johnson BE, Mentzer S. Broncholoalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease. Harrison's Principles of Internal Medicine. 2001; 121:42-47.
  • Breathnach OS, Kwiatkowski DJ, Finkelstein DM, Godleski J, Sugarbaker DJ, Johnson BE, Mentzer S. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg 2001; 121:42-7. PubMed
  • Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE, Lander ES, Meyerson M. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol 2000; 18:1001-5. PubMed
  • Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris M, Klein P, Li Xin, Ramies D, Johnson DH, Miller V. Tribute - A Phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2006.
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Raimes DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagri S, Hillan KJ. Mutations in the Epidermal Growth FActor Receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology 2006.
  • Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, Feld R, Shepherd FA, Johnson DH, Grant SC, Aisner J, Johnson BE. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997; 89:1782-8. PubMed
Hide